Vanguard Group
CYCN icon

Vanguard Group’s Cyclerion Therapeutics CYCN Stock Holding History

Vanguard Group’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$29.8K Hold
23,490
– – ﹤0.01% 4289
2025
Q3 		$54K Hold
23,490
– – ﹤0.01% 4293
2025
Q2 		$68.4K Hold
23,490
– – ﹤0.01% 4170
2025
Q1 		$58K Hold
23,490
– – ﹤0.01% 4184
2024
Q4 		$75.6K Hold
23,490
– – ﹤0.01% 4185
2024
Q3 		$60.6K Hold
23,490
– – ﹤0.01% 4235
2024
Q2 		$54K Hold
23,490
– – ﹤0.01% 4285
2024
Q1 		$75.2K Hold
23,490
– – ﹤0.01% 4266
2023
Q4 		$78.7K Sell
23,490
-17,041
-42% -$49.3K ﹤0.01% 4325
2023
Q3 		$139K Sell
40,531
-40,638
-50% -$147K ﹤0.01% 4308
2023
Q2 		$334K Sell
81,169
-1,408
-2% -$7.29K ﹤0.01% 4218
2023
Q1 		$717K Hold
82,577
– – ﹤0.01% 4011
2022
Q4 		$1.08M Buy
82,577
+42
+0.1% +$497 ﹤0.01% 3884
2022
Q3 		$1.42M Sell
82,535
-5,173
-6% -$88.9K ﹤0.01% 3879
2022
Q2 		$963K Hold
87,708
– – ﹤0.01% 4102
2022
Q1 		$1.95M Sell
87,708
-5,810
-6% -$140K ﹤0.01% 3969
2021
Q4 		$3.22M Buy
93,518
+21,917
+31% +$1.04M ﹤0.01% 3847
2021
Q3 		$4.4M Buy
71,601
+424
+0.6% +$27.7K ﹤0.01% 3743
2021
Q2 		$5.55M Sell
71,177
-12,280
-15% -$769K ﹤0.01% 3538
2021
Q1 		$4.66M Buy
83,457
+198
+0.2% +$14.9K ﹤0.01% 3568
2020
Q4 		$5.09M Sell
83,259
-2,712
-3% -$185K ﹤0.01% 3345
2020
Q3 		$10.5M Buy
85,971
+29,891
+53% +$3.42M ﹤0.01% 2760
2020
Q2 		$6.63M Sell
56,080
-8,560
-13% -$716K ﹤0.01% 2963
2020
Q1 		$3.42M Buy
64,640
+59
+0.1% +$4.21K ﹤0.01% 3132
2019
Q4 		$3.51M Sell
64,581
-179
-0.3% -$16.7K ﹤0.01% 3284
2019
Q3 		$15.7M Buy
64,760
+8,743
+16% +$1.89M ﹤0.01% 2592
2019
Q2 		$12.8M Buy
+56,017
New +$15.9M ﹤0.01% 2716

Other funds holding CYCN

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group's CYCN Position: Q4 2025 in Review

Vanguard Group held its Cyclerion Therapeutics (CYCN) position steady in Q4 2025 at 23,490 shares worth $29.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4289.

Vanguard Group first reported a position in CYCN in Q2 2019 and has held it in 27 quarters since. The position peaked at $15.7M in Q3 2019. 19 funds tracked by Wall St. Rank hold CYCN as of Q4 2025.

  • Vanguard Group held 23,490 shares of Cyclerion Therapeutics worth $29.8K as of Q4 2025.
  • Vanguard Group left its Cyclerion Therapeutics share count unchanged in Q4 2025.
  • Cyclerion Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4289 holding.
  • Vanguard Group first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • Vanguard Group's Cyclerion Therapeutics position peaked at $15.7M in Q3 2019.
  • 19 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.